Drug Combo Proves Powerful Against Lung Cancer Hilton NY

A two-drug combination treatment in Hilton proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Alissa Huston
(585) 375-3746
601 Elmwood Ave
Rochester, NY
GORDON PHILLIPS, MD
(585) 275-0784
601 Elmwood Avenue
Rochester, NY
Anthony A Bibawy, MD
585-755-7220
601 Elmwood Ave # 704
Rochester, NY
Julia Ladd Smith, MD
585-922-4020
1425 Portland Ave
Rochester, NY
Louis S Constine, MD
716-275-5622
601 Elmwood Ave PO Box 647,
Rochester, NY
David N Korones
(585) 275-2981
601 Elmwood Ave
Rochester, NY
Luke Otto Schoeniger
(585) 273-4713
601 Elmwood Ave
Rochester, NY
JESSICA KLEINER, MD
(585) 475-8700
211 White Spruce Boulevard
Rochester, NY
Andrew Dede Liman, MD
585-486-0600
125 Red Creek Dr
Rochester, NY
Norma Berg Lerner, MD
585-275-2821
601 Elmwood Ave # 777
Rochester, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Breast Cancer Survival Hilton NY
Breast cancer is a physically and emotionally traumatizing disease. A study underrtaken at the Harvard School of Public Health examined four observational studies to determine whether physical activity could improve quality of life after a breast cancer diagnosis and on increased breast cancer survival.
- Fungal Infection Treatments Hilton NY
- Hormone Therapy for Lung Cancer Hilton NY
- Genetic Clues for Skin Cancer Therapies Hilton NY
- Side Effect Of Chemotherapy Drugs Hilton NY
- Delayed Prostate Cancer Therapy Hilton NY
- Risks for Childhood Cancer Survivors Hilton NY
- Hormone Therapy for Breast Cancer Hilton NY
- Exercise for Prostate Cancer Hilton NY